Targeted Sequencing Resequencing Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Targeted sequencing and resequencing selectively interrogates predefined genomic regions using methods such as amplicon sequencing, hybrid capture panels, and targeted enrichment workflows. The broader next-generation sequencing ecosystem, encompassing instruments, consumables, and data-analysis services, is valued in the tens of billions of dollars globally, with targeted approaches representing a substantial and expanding share. Rapid adoption across clinical laboratories, academic research centers, and contract research organizations has sustained double-digit expansion.

• •The broader NGS market is estimated at roughly $14-16 billion in 2025, with targeted sequencing representing a significant and fast-growing segment.
• •NGS data-analysis services alone are projected to grow from about $1.06 billion in 2024 to nearly $3.65 billion by 2032.
• •NGS services as a category are forecast to rise from approximately $3.80 billion in 2025 to $8.77 billion by 2030.

Proliferating applications in oncology, especially liquid biopsy and minimal residual disease monitoring, remain the primary engine, as targeted panels offer cost-effective, high-sensitivity alternatives to whole-genome approaches. Wider availability of automated library-preparation workflows and streamlined bioinformatics pipelines is reducing turnaround times, making targeted resequencing practical for routine clinical use. Government funding for genomics programs, expanding newborn-screening initiatives, and the rise of companion diagnostics tied to targeted therapies collectively underpin demand.

• •Falling per-sample sequencing costs and improved multiplexing throughput are making large-scale targeted resequencing economically viable.
• •Growth in precision-medicine programs and companion-diagnostics approvals is creating sustained demand for targeted gene panels.
• •Expanding adoption in non-healthcare domains, such as agrigenomics, pathogen surveillance, and environmental DNA monitoring, is diversifying the user base.

The market is commonly segmented by product type, including sequencing instruments, library-preparation kits, target-enrichment reagents, and data-analysis software, as well as by application areas such as oncology, infectious disease, reproductive health, and pharmacogenomics. Geographically, North America commands the largest share, driven by substantial R&D investment, a dense clinical laboratory infrastructure, and favorable regulatory pathways. The Asia-Pacific region is the fastest-growing area, fueled by government genomics initiatives, expanding biotech manufacturing, and increasing healthcare expenditure.

• •North America leads in market share, supported by established academic medical centers and early adoption of NGS-based clinical tests.
• •Asia-Pacific is projected as the highest-growth region, with China, India, and Japan investing heavily in genomic infrastructure.
• •Europe holds a significant share, particularly in academic research consortia and population-scale genomics programs.

Who are the notable companies in the industry?

The competitive environment is moderately concentrated, with a small number of vertically integrated players dominating instrument and consumable manufacturing, while a broader tier of specialty firms focuses on library-preparation reagents, target-enrichment technologies, and bioinformatics software. The value chain spans from upstream reagent and equipment suppliers through midstream service laboratories and downstream data-analysis platforms, with some participants operating across multiple stages. Manufacturing and R&D capacity is heavily concentrated in North America, Western Europe, and key East Asian hubs, reflecting established biotech clusters and supply-chain infrastructure.

• •The market exhibits moderate consolidation at the top, with integrated producers controlling core sequencing-platform ecosystems alongside a fragmented layer of niche enrichment and software providers.
• •Primary technology routes include amplicon-based sequencing, hybridization-capture target enrichment, and increasingly, CRISPR-based enrichment methods for highly multiplexed panels.
• •Regional capacity is concentrated in North America and the EU for high-end instrument production and advanced reagent development, with Asia-Pacific rapidly expanding consumable-manufacturing footprint.

What are the recent trends and outlook?

Single-cell targeted sequencing, spatial transcriptomics, and long-read-targeted approaches are emerging as high-growth sub-segments, offering finer resolution for complex tissue and microbiome studies. Integration of artificial-intelligence-driven variant interpretation is expected to shorten clinical reporting timelines and improve diagnostic accuracy. Over the 2026-2030 horizon, the market is likely to maintain a 15% annual growth trajectory, underpinned by continued clinical test expansion, reimbursement-code adoption, and broadening application into direct-to-consumer and population-health screening programs.

• •Long-read targeted sequencing is gaining traction for resolving structural variants and repetitive regions inaccessible to short-read platforms.
• •AI and machine learning are increasingly embedded in analysis pipelines for automated variant calling, prioritization, and clinical report generation.
• •Point-of-care and decentralized targeted sequencing devices are expected to broaden access in emerging markets and community-hospital settings.